on HAL Allergy B.V.
HAL Allergy and InfectoPharm Form Strategic Partnership for ENT Digital Health
HAL Allergy and InfectoPharm announce a strategic partnership focusing on digital health applications in ENT. This multi-year commercial agreement aims to enhance patient care with innovative treatment solutions.
The partnership leverages HAL Allergy's expertise in allergen immunotherapies and InfectoPharm’s experience in innovative healthcare solutions. The collaboration starts with the promotion of ‘Meine Tinnitus App’, a DiGA added to the DiGA-Directory, offering interactive tinnitus counselling adhering to medical guidelines.
This app allows patients to integrate therapy into their lives flexibly, easing the burden on ENT specialists. The companies plan to expand their digital portfolio in the ENT field by the end of 2026, aiming to combine conventional and digital treatments effectively.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HAL Allergy B.V. news